In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • The Effects of Brain Derived Neurotrophic Factor Val66Met Polymorphism on Cervical Spondylotic Myelopathy

    Final Number:
    1250

    Authors:
    Kingsley O. Abode-Iyamah MD; Kirsten Stoner M.Eng; Andrew James Grossbach MD; Stephanus Viljoen MD; Colleen McHenry B.Sc.; Michael Petrie B.Sc.; Nader S. Dahdaleh MD; Nicole Grosland; Richard Shields PT, Ph.D; Matthew A. Howard MD

    Study Design:
    Clinical Trial

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2015 Annual Meeting

    Introduction: Cervical spondylotic myelopathy (CSM) is the leading cause of spinal cord related disability in the elderly. It results from degenerative narrowing of the spinal which causes spinal cord compression. This leads to gait instability, weakness, numbness and, or urinary dysfunction. There has been indirect data that implicates a genetic component to CSM. Such a finding may contribute to the variety in presentation and outcome in this patient population. The val66met polymorphism, a mutation in the BDNF gene, has been implicated in a number of brain and psychological conditions, and here we investigate its role in CSM.

    Methods: Ten subjects diagnosed with CSM were enrolled in this prospective study. Baseline subjective clinical evaluation using mJOA, Nurick and SF-36 were collected. In addition each subject underwent objective testing with gait kinematic assessments as well as hand functioning using the Purdue Peg Board. Blood samples were analyzed for the BDNF Val66met mutation.

    Results: The prevalence of the BDNF Val66met mutation in this study was 60% amongst CSM patients compared to 32% in the general population. Individuals with abnormal met allele had worse baseline mJOA, and Nurick scores. Moreover, baseline gait kinematics and hand functioning testing were worse compared to their wild type counterpart.

    Conclusions: BDNF Val66met mutation has a higher prevalence in CSM compared to the general population. Those with BDNF mutation have a worse clinical presentation compared to the wild type counterpart. BDNF may play a role in the development and severity of cervical spondylotic myelopathy.

    Patient Care: This study help to better understand the pathophysiology of CSM. Additionally the findings could help improve the management of these patients.

    Learning Objectives: 1. BDNF polymorphism is more prevalent in CSM. 2. Patients with BDNF val66met mutation present with worse clinical presentation based on nurick and mJOA scores. 3. CSM patients with val66met mutation report worse functioning based on SF-36 questionaire compared to their wild-type counterpart. 4. CSM patients with val66met mutation have worse gait at presentation.

    References: 1. Bull J, el Gammal T, Popham M. A possible genetic factor in cervical spodylosis. Br J Radiol 1969;42:9-16 2. Lestini W, Wiesel SW. The pathogenesis of cervical spondylosis. Clin Orthop Relat Res 1989;239:69-93 3. Palmer P, Stadalnick R, Arnon S. The genetic factor in cervical spondylosis. Skeletal Radiol 1984;11:178-82 4. Sambrook P, MacGregor AJ, Spector TD. Genetic influences on cervical and lumbar disc degeneration: A magnetic Resonance imaging study in twins. Arthritis Rheum 1999;42:366-72 5. Yoo K, Origiano TC. Familial cervical spondylosis. J Neurosurgery 1998;89:139-41 6. Patel A, Spiker W, Daubs M, et al. Evidence of an inherited predisposistion for cervical spondylotic myelopathy. Spine 2012. 37: 26-29 7. Wang ZC, Chen XS, Wang da W, et al. The genetic association of vitamin D receptor polymorphisms and cervical spondylotic myelopathy in Chinese subjects. Clin Chim Acta 2010;411:794–7. 8. Wang ZC, Shi JG, Chen XS, et al. The role of smoking status and collagen IX polymorphisms in the susceptibility to cervical spondy- lotic myelopathy. Genet Mol Res 2012;11:1238–44. 9. Setzer M, Hermann E, Seifert V, et al. Apolipoprotein E gene polymorphism and the risk of cervical myelopathy in patients with chronic spinal cord compression. Spine (Phila Pa 1976) 2009;33:497–502. 10. Egan M. Kojima M. The BDNF Val66met Polymorphism affects Activity-dependent secretion of BDNF and Human memory and hippocampal function. 11. Veves-Pereira, Mundo E. The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorders: Evidence from a family-based association. AM J Hum Genet. 2002; 73:651-655 12. Strube W, Nitsche MA, Wobrock T, Bunse T, Rein B, Herrmann M, Schmitt A, Nieratschker V, Witt SH, Rietschel M, Falkai P, Hasan A. BDNF-Val66Met-Polymorphism Impact on Cortical Plasticity in Schizophrenia Patients: A Proof-of-Concept Study. Int J Neuropsychopharmacol. 2014 Oct 31. 13. Sako W, Murakami N, Izumi Y, Kaji R. Val66Met polymorphism of brain-derived neurotrophic factor is associated with idiopathic dystonia.J Clin Neurosci. 2014 Dec 15. pii: S0967-5868(14)00592-X. 14. Benzel EC. Cervical laminectomy and dentate ligament section for cervical spondylotic myelopathy. J Spinal Disord. 1991 15. Lu YJ, Wu CS, Li HP. Aberrant methylation impairs low density lipoprotein receptor-related protein 1B tumor suppressor unction in gastric cancer. Genes Chromosomes Cancer 49: 412-424. 2010 16. Wang ZC, Hou XW, Shao Jiang. HIF-1x polymorphism in the susceptibility of cervical spondylotic yelopathy and its outcome after anterior cervical fusion. Plos One. 2014 17. Wang D, Liu W, Cao Y,. BMP-4 polymorphisms in the susceptibility of Cervial spondylotic myelopathy and its outcome after anterior cervical corpectomy and fusion. Cell Physiol Biochem 32: 210-217 (2013) 18. James S. Harrop, MD,*† Swetha Naroji, BA, Mitchell Maltenfort, PhD,* D. Greg Anderson, MD,† Todd Albert, MD,*† John K. Ratliff, MD,*† Ravi K. Ponnappan, MD,† Jeffery A. Rihn, MD,† Harvey E. Smith, MD,† Alan Hilibrand, MD,*† Ashwini D. Sharan, MD,*?and Alexander Vaccaro, MD, PhD*†. A Clinical and Radiographic Evaluation and Correlation to Cervical Spondylotic Myelopathy. Spine 2010;35:620–624 19. Tetreault LA, Dettori JR. Systematic review of MRI characteristics that affects treatment decision making and predict clinical outcome in patients with sondylotic myelopathy. Spine 2013. 20. Shimizu E, Hashimoto K. Ethnic difference of the BDNF polymorphism frequencies: The possibility to explain ethnic mental tratis. AM J Med Genet B Neuropsychiatr Genet. 2004 21. Steven C. Cramer. Increased prevalence of Val66met BDNF genotype among subjects with cervical dystonia. Neurosci Lett. 2010 22. Qin L, Deqlang J, Parauda S, Carmel J, Ratan RR, Lee FS, Cho S. An adaptive role for BDNF val66met polymorphism in motor recovery in chronic stroke. J Neurosci. 34(7):2493-502. 2014 23. Petryshen TL, Saveti PC, Aldinger KA, Fry B, Fan JB, Schaffner SF, Waggoner SG, Tahl AR, and Sklar P. Population genetic study of the brain-derived neurotrophic factor (BNDF) gene. Mol Psychiatry. 15(8):810-5. 2010. 24. J.P. Kuhtz-Buschbeck a,*, K. Jo ¨hnk a, S. Ma ¨der a, H. Stolze a, M. Mehdorn. Analysis of gait in cervical myelopathy. Gait and Posture 9 (1999) 184–189. 25. Nakajima H1, Uchida K, Yayama T, Kobayashi S, Guerrero AR, Furukawa S, Baba H. Targeted retrograde gene delivery of brain-derived neurotrophic factor suppresses apoptosis of neurons and oligodendroglia after spinal cord injury in rats. Spine (Phila Pa 1976). 2010 Mar 1;35(5):497-504 26. Sasaki M1, Radtke C, Tan AM, Zhao P, Hamada H, Houkin K, Honmou O, Kocsis JD. BDNF-hypersecreting human mesenchymal stem cells promote functional recovery, axonal sprouting, and protection of corticospinal neurons after spinal cord injury. J Neurosci. 2009 Nov 25;29(47):14932-41.

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy